Neurofit-Aribio Collaborate to Develop 'Next-Generation Dementia Diagnosis Platform'

Neurofit, a specialized company in brain disease imaging artificial intelligence (AI) solutions, announced on the 27th that it will jointly develop a 'next-generation Alzheimer's diagnosis platform' with Aribio, a bio company developing treatments for degenerative brain diseases.

In addition to their ongoing collaboration on the development of oral Alzheimer's dementia treatments and related data research and development (R&D), the two companies plan to combine Neurofit's brain imaging analysis technology using magnetic resonance imaging (MRI) with Aribio's blood-based biomarker testing to create a new Alzheimer's diagnosis platform that overcomes the limitations of existing testing methods.

Specifically, the two companies plan to develop a diagnostic platform that can predict amyloid-beta protein positive risk groups early by conducting MRI analysis and blood-based biomarker tests before amyloid positron emission tomography (PET) imaging. The strategy is to reduce unnecessary amyloid-PET scans and actively utilize a testing method with higher medical accessibility.

Bin Jungil, CEO of Neurofit, said, "By participating in Aribio's AR1001 global phase 3 clinical trial, we expect to secure extensive medical data and achieve meaningful research outcomes in various fields," adding, "If this platform is successfully developed, it will drastically reduce medical costs associated with dementia diagnosis and treatment and improve patient convenience."

Jung Jaejun, CEO of Aribio, also stated, "Since accessibility and convenience are paramount for Alzheimer's patients and their families, we are developing a safe and easy-to-take oral pill treatment," and added, "We expect to maximize accessibility to Alzheimer's diagnosis through the synergy of Neurofit's brain imaging analysis technology and blood-based diagnostic methods."

This content was produced with the assistance of AI translation services.